Poniard cancer drug misses goal in lung cancer

Courtesy Newsvine - business  Mon, 11/16/2009 - 08:07

Poniard Pharmaceuticals Inc. said Monday its cancer drug candidate picoplatin did not help lung cancer patients live longer, sending its shares plunging in early trading.


 

Related items

Unusual 11 Mid-Day Movers 09/23: BNIVD, TSTR, ANTH,...
Bionovo, Inc. (Nasdaq: BNVID) 56.6% HIGHER; announced that the U.S. FDA accepted the Company's Chemistry, Manufacturing and Controls plan for its lead drug candidate, Menerba®, in a Type "B"...

Analyst says new Levadex data could lift MAP stock
MAP Pharmaceuticals Inc. plans to share additional data from testing of its migraine drug candidate Levadex next week, and a Wedbush Morgan analyst said the results could boost MAP's share...

Morning Movers 02/07: (SATC) (BMTI) (CSTR) (MNI)...
Satcon Technology Corporation (NASDAQ: SATC) 24.3% HIGHER; announced a partnership with Great Wall Computer Company Limited. The partnership will position Satcon to capitalize on the...

BlueAnt UNOTPBAX53 X5 Bluetooth Stereo Headphone...
The X5 Stereo Bluetooth Headset is a portable multi-function device utilizing the latest cutting edge technologies allowing you to stream high quality music and make voice calls using a...

Uniden TRU9496 2-Line Corded/Cordless Digital...
With the Uniden TRU9496 5.8 GHz Digital 2-Line Expandable Phone System is the next generation of 5.8 GHz cordless phones. It's a full-featured digital answerer, with a Dialing keypad and a...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
CAPTCHA
We apologize for the inconvenience. Please help fight spam.
business.marc8.com